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Abstract
Background: Illness Management and Recovery (IMR) is intended to provide a structured psychosocial programme
that helps to manage the disabling effects of severe mental illnesses such as schizophrenia and bipolar disorders. It
is curriculum based and aims to improve different aspects of illness management and recovery through
interventions such as goal-setting, psycho-education, coping and social skills training. Its overall aim is to improve
illness outcomes and support subjective and objective recovery. To date there have been four RCTs on IMR; as
these yielded mixed results, further research is needed. Our hypotheses aim to test the interrelatedness assumed in
Mueser’s Conceptual Framework for IMR for the many aspects of illness management, illness management
outcomes and recovery.
Methods/design: This randomised multi-centre, single-blinded clinical trial is intended to compare IMR with
treatment as usual for 200 outpatient clients with a severe and persistent mental illness (SMI). We will investigate
whether IMR leads to better illness management, fewer symptoms and fewer relapses, and also to better subjective
and objective recovery. The primary outcome measure is the score on the client version of the Illness Management
and Recovery Scale. Secondary outcome measures are the clinician version of the Illness Management and
Recovery scale, measures of illness management, coping, symptoms, the number of relapses, and measures of
recovery. Measurement will take place before randomisation, and 12 and 18 months after randomisation.
Discussion: Overall, our study has the following strengths: 1.) our use of an RCT design in a country where the
earlier RCTs on IMR were not conducted; 2.) the fact that participants will consist not only of people with a
diagnosis of schizophrenia, but also of those with various types of SMI; 3.) our inclusion of 200 participants; and
4.) the fact that we will explore the working mechanisms described in Mueser’s Conceptual Framework for IMR.
Finally, 5.) because the RCT will be conducted in everyday clinical practice, we believe that the generalisability of
our results will be good.
Trial registration: The Netherlands National Trial Register (identifier: NTR 5033). Date registered: 13 January 2015.
Keywords: Illness management and recovery, IMR, Self management, Severe mental illness, Schizophrenia, Training,
Recovery, Personal goals
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Background
Introduction
Due to the disabling effects of their illness, it is hard for
people with severe and persistent mental illnesses (SMI)
such as schizophrenia or a bipolar disorder to participate
fully in society. Though they have the same aspirations
as other people, these wishes are harder to realize, due
not only to their illness, but also to barriers within
society (such as stigma) [1]. Mental-health care should
therefore include interventions that support individual
recovery and contribute to self-determination and well-
being, and also to skills for illness self-management and
for fulfilling valued roles in domains such as work, social
connections and housing [2, 3].
In recent years, various psychosocial interventions
have been developed to support recovery, such as the
Cognitive Adaptation Training (CAT) [4], the Wellness
Recovery Action Plan (WRAP) [5] and the Boston
Psychiatric Rehabilitation (PR) Approach [6].
Over the last decade, a promising new programme for
people with SMI has been developed: Illness Manage-
ment and Recovery (IMR) [2], a programme that com-
bines psychosocial interventions such as psycho-
education with aspects of cognitive behavioural therapy,
skills training, peer support and rehabilitation. These in-
terventions aim to help participants gain greater control
of their problems through illness management, and also
to support their recovery.
The IMR programme was based on an empirical re-
view of the research literature on teaching illness self-
management strategies to people with SMI [7]. It was
also part of the National Implementing Evidence-Based
Practices Project in the U.S. [8, 9]. In themselves, the
different parts of the IMR programme were not new; the
newness lay in offering them as an integrated package.
The theoretical foundation of IMR rests on two
models. The first, the trans-theoretical model, holds that
people are more motivated to acquire new behaviour if
the types of intervention are adjusted to the stage of
change they are in. This makes it is easier for people to
become aware of their problems, to take decisions, and
to implement and sustain change [10, 11].
The second model is the stress-vulnerability model
[2], which holds not only that mental health problems
originate from the interaction between biological vulner-
ability and sources of stress in the environment, but also
that people differ in their coping ability [12, 13]. In line
with the stress-vulnerability model, IMR -trainers need to
teach participants the basics of illness (self-) managemen-
t—enabling them, for example, to reduce substance use,
improve adherence to medication, increase coping and so-
cial support, and become involved in meaningful activities.
This may improve illness outcomes such as symptoms, re-
lapse, and hospitalisation.
By combining better illness management with the pur-
suit of personal goals, progress may be made towards re-
covery. In Mueser’s model, the IMR programme may
also lead directly to recovery, though it should be noted
that Mueser differentiates between subjective recovery
(perceived recovery, sense of purpose, and personal
agency) and objective recovery (role and social function-
ing) [2] (see Fig. 1).
IMR is seen as an Evidence Based Practice (EBP) by
the researchers who designed it and by the Substance
Abuse and Mental Health Services Administration
(SAMSHA) in the U.S., who reasoned that its compo-
nents were evidence based [7, 9]. However, research on
the overall programme was needed.
In a review conducted in 2011, it appeared that
three randomised controlled trials (RCTs), three
quasi-controlled trials and three pre-post trials on the
overall programme had been conducted [14]. The re-
sults of one further RCT have also been published
[15]. The RCTs differed from each other with regard
to setting, participant number and diagnoses, the
length and format of IMR, the trainers’ training and
their qualifications, the intensity of supervision of the
trainers, the number and timing of measurements,
the type of control group and the fidelity of the im-
plementation of IMR. The results of the four RCTs
are presented in Table 1.
The first three RCTs compared IMR with care as usual
(CAU) [16–18]. On the overall score of the client ver-
sion of the Illness Management and Recovery Scale
(IMRS [19], two of these studies showed significantly
positive results for clients assigned to IMR, with respect-
ive effect sizes of .36 [18] and .29 [16]. The other study
found significant improvement in IMRS scores only if
the analyses were limited to sites with high IMR fidelity
[17]. On the overall score of the clinician version of the
IMRS, all three of these studies showed significantly
positive results for clients assigned to IMR, with respect-
ive effect sizes of .28 [17], .39 [18] and .34 [14, 16]. On
the overall score of both the client version and the clin-
ician version of the IMRS, the more recent RCT of
Salyers—in which IMR was tested against an active con-
trol group [15]—showed no significant differences be-
tween the experimental and control group.
In all four studies, additional significantly positive re-
sults for IMR were found on client-reported knowledge
in one study [17], on client-reported coping in another
study [16], on clinician-reported quality of life in a third
study [18], and on observer-rated psychiatric symptoms
in two of these studies [16, 18]. These results were either
not found in the other RCTs, or the domains in question
were not measured. No significant outcomes were found
on objective outcomes such as medication dosage,
employment, or hospitalisations and emergency visits.
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While Salyers found no significant differences between
IMR and the active control group on any of the domains
measured (Table 1), the respective participation rates in
the two interventions were only 28 and 17 % [15].
These mixed results indicate the need for more
research.
We aim to use an RCT design to study the effects of
IMR in a Dutch context. On both of the IMR scales, we
expect positive results of the sort found in the earlier
studies that used CAU as a control [16–18]. We also
hope to gain additional information with regard to
symptoms, coping and recovery, on which the earlier re-
sults differed. By using different outcome measures of
illness management, illness outcomes, and recovery, our
study will provide a thorough measurement of the ef-
fects of IMR.
Before designing the main study, we conducted a pilot
study to explore the feasibility of an RCT and to provide
practical guidelines for its implementation. This study
suggested that an RCT on IMR was feasible: not only
could sufficient participants be recruited for all six
IMR-groups, which could be established with good
mean fidelity, but support for a broader implementa-
tion of IMR could also be identified [20].
Research aims
The aim of this study is to compare the effectiveness of
the IMR programme with that of CAU in people with
SMI. Specifically, we wish to compare the effects of
‘IMR + CAU’ with those of ‘CAU only’ on illness man-
agement and recovery.
Hypotheses
We have two primary hypotheses and four secondary
hypotheses. The first primary hypothesis is that IMR +
CAU (IMR offered in group format) leads to better ill-
ness management and to fewer symptoms and relapses
than CAU only. The second primary hypothesis is that
IMR + CAU leads to better ‘subjective’ and ‘objective’ re-
covery than CAU only. We thus expect a condition x
time interaction effect of the IMR + CAU group over the
CAU-only group.
The first secondary hypothesis is that the cost-utility
of IMR + CAU is better than that of CAU.
We intend to explore the working mechanisms of
IMR by testing the second secondary hypothesis that
better illness management (i.e. getting greater psychi-
atric insight, better coping, more social support, less
addiction and better service engagement) leads to
fewer symptoms and relapses. We also intend to test
the third secondary hypothesis that better ‘distal
outcomes’ (i.e. recovery, see Fig. 1) result from a
combination of better ‘proximal outcomes’ (i.e. better
illness management and fewer symptoms and re-
lapses) and progress on personal goals [2]. Finally, we
expect that any improvement resulting from IMR +
CAU will be associated with the fidelity of IMR im-
plementation (fourth secondary hypothesis).
Design
This research project entails a randomised controlled
trial in which clients who provide written informed
consent will be assigned to the experimental condi-
tion (IMR) or the control group. The experimental
group will consist of clients who participate in the
IMR programme (which will be offered in a group
format) and also get CAU. The control group will re-
ceive CAU.
Measurement is planned to take place before random-
isation and at 12 and 18 months after randomisation.
Fig. 1 Conceptual Framework for the Illness Management and Recovery programme of Mueser et al. [2]
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Participants
The participants in the study will be adult SMI out-
patient clients aged between 18 and 65 who have
given written informed consent. There will be three
exclusion criteria: having already participated in IMR
training, being unable to give informed consent due
to mental incompetence, and insufficient knowledge
of the Dutch language.
Most participants will have a psychotic disorder or
a schizoaffective disorder with or without comorbid
disorders such as substance abuse and personality
disorders.
Recruitment procedure
Participants will be recruited from 14 community
mental health teams at 11 branches of two mental
health institutions in the greater Rotterdam area (the
Netherlands). Eight teams throughout the city of
Rotterdam serve an urban area of approximately 1.2
million inhabitants, one team serves a more rural
environment to the west of Rotterdam, and five
teams serve the neighbouring city of Dordrecht
(120,000 inhabitants) and four smaller communities
of 20,000–35,000 inhabitants.
During interviews with an assistant researcher, the
caseloads of all clinicians in these teams will be
assessed for their potential suitability for IMR. The
clinicians will ask selected clients to participate in
IMR and about their willingness to be informed about
the study. If clients express interest and agree to be
contacted by an assistant researcher for more detailed
information, the assistant researcher will explain the
Table 1 Results of four completed RCTs on IMR (by studya,b)
Hasson-Ohayon et al. 2007 [17] Levitt et al. 2009 [18] Färdig et al. 2011 [16] Salyers et al. 2014 [15]
Consumer report
IMR Scale. NS .36 .29 NS
Patient activation NS
Recovery NS NS
Hope NS
Coping NS .14–.19c
Knowledge about mental illness .14d
Psychiatric symptoms NS
Quality of life, community functioning,
and social support
NS NS
Medication adherence NS
Clinician report
IMR Scale .28 .39 .34
Quality of life, community functioning,
and social support
.52
Substance abuse NS
Observer-rated psychiatric symptoms −.20 .38 NS
Interviewer−rated Quality of Life NS
Objective outcome
Hospitalizations and emergency NS NS NS NS
Visits
Employment NS
Medication dosage NS
Inpatient admission NS
Inpatient psychiatric admission NS
Length of inpatient stay NS
Length of inpatient psychiatric stay NS
aThe results of the studies of Hasson-Ohayon et al. [17], Levitt et al. [18], Färdig et al. [16] and notes b, c and d are taken from McGuire et al. [14]
bResults reflect comparisons from baseline to the longest follow-up period. Studies reported only one scale for each category. Only significant (p,.05) effect sizes
(Cohen’s d) are reported. Effect sizes for Färdig et al. [16] are reported as η2. A blank cell indicates that the variable was not measured. NS: not significant
c Range from the four of eight subscales of the Ways of Coping Scale with significant results
d Knowledge and goals subscale of the consumer-reported IMR Scale
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research goals, randomisation procedure and the three
times of measurement. Clients will then be asked
whether they want to participate in the study. After
written informed consent has been given, the baseline
interview will be followed by randomisation.
Intervention
In essence, IMR is a structured training consisting of
11 modules, practitioner guides and handouts for par-
ticipants. The 11 modules are 1.) Recovery Strategies,
2.) Practical Facts about Mental Illness, 3.) Stress-
Vulnerability Model, 4.) Building Social Support, 5.)
Using Medication Effectively, 6.) Drug and Alcohol
Use and Treatment Strategies, 7.) Reducing Relapses,
8.) Coping with Stress, 9.) Coping with Problems and
Persistent Symptoms, 10.) Getting Your Needs Met in
the Mental-health System, and 11.) Health for You.
The IMR training will be given at the participating
institutes in a group format with weekly sessions. The
original American text [19] has been translated into
Dutch and will be adapted to the Dutch context if
necessary.
During the first module, participants will decide
which personal goals they want to work on during
the programme. For the first half of each 90-min ses-
sion, some will work on their goals in the group.
During the second half, all participants will work with
the help of the handouts on the subjects of the
modules.
Our pilot study showed that most modules will
require an average of three to four sessions. Each
IMR group will be guided by two trainers, who will
use 1.) motivation-enhancement strategies such as
conveying confidence and exploring the pros & cons
of change; 2.) educational strategies (psycho-education)
such as interactive teaching, breaking down informa-
tion, and checking for understanding; and 3.) cognitive-
behavioural techniques such as shaping, modelling
and role playing. Peer-group support and coping &
social skills training are integral to IMR. Homework
assignments will be provided. Workbooks and home-
work assignments can be accessed through an e-
health module.
IMR model fidelity
To promote the fidelity of the intervention, the trainers
will be experienced clinicians (mostly psychiatric nurses)
who will receive a 2-day course in teaching IMR before
the study starts and who will attend supervision once
every 2 weeks for 2 h. Twice a year, all IMR trainers will
come together for a morning or afternoon of additional
training.
To measure whether the IMR-programme is imple-
mented according to the original intent, the researchers
will determine model fidelity using the IMR fidelity scale
and the IMR General Organisational Index (GOI) [19,
21]. These scales have been translated, and the principal
investigator was trained in their use by two American
specialists (M.P. Salyers, Ph.D. and A. Mc Guire, Ph.D,
both of UIPUI, University of Indianapolis USA). We will
also use the Illness Management and Recovery Treat-
ment Integrity Scale (IT-IS) [22], which gives more pre-
cise information on the quality of the trainers’
interventions. These fidelity scales will be applied by the
principal researcher and a research assistant, scoring in-
dependently according to a protocol. For one team, fi-
delity measurement takes almost a day, and consists of
interviews with two participants and the two trainers, in
addition to observation of one session, and checking
forms. The researchers will give periodic feedback in the
supervision groups on the results of the fidelity
measurements.
Care as usual
CAU will involve outpatient case management, medica-
tion and rehabilitation services, with no restrictions on
anything. The usual frequency of treatment contacts is
1.) one face-to-face contact with a mental health nurse
every 2 weeks, and 2.) contact with a psychiatrist when
indicated and no less than once a year. To indicate what
CAU actually comprised, we will register the use of care
in the control group.
Instruments
Data will be collected on bio-demographic variables, ill-
ness management, illness outcomes and recovery. For an
overview of instruments, data sources and times of
measurement, see Table 2.
Bio-demographic variables
Bio-demographic variables and psychiatric history
will be collected at baseline during the interviews
with the clients and the clinician; they will be
checked in the electronic client files. The diagnoses
were made earlier on the basis of a clinical interview
by psychiatrists on the community mental health
team, and will be collected during the interviews
with clinicians and checked in the electronic client
files.
Illness management and illness outcomes
The primary outcome measure is the self-rated IMRS
[23, 24] with 15 items completed by clients themselves.
One of the secondary outcome measures is the clinician-
rated IMRS [23, 24]. The IMR scales have good validity
and moderate reliability [25, 26]. To identify and correct
discrepancies, the Dutch translation has been independ-
ently back-translated into English and compared with
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the original version. Evidence has been provided for the
reliability and validity of this Dutch version [27].
These two IMR scales are not unidimensional mea-
sures [25, 28]. Three factors were found: ‘Coping with
Illness Outcome’, ‘Knowledge and Goals’, and ‘Effective
Medication Use/Reduced Alcohol and Drug Abuse’ [25].
In terms of Mueser’s framework, the items of these two
IMR scales mainly concern aspects of illness manage-
ment and illness outcomes.
Additional illness-management scales Given the lim-
ited number of items in the IMR scales, we will also
assess illness management using other validated and
more comprehensive scales, assessing coping, social
support, treatment compliance, insight into illness,
and problems with alcohol and drugs. To measure
these secondary outcome variables, we will use the
following:
The coping self-efficacy scale (CSES [29]), 13-items.
This scale has good internal reliability and three fac-
tors: using problem-focused coping (six items), stop-
ping unpleasant emotions and thoughts (four items),
and getting support from friends and family (three
items). Internal consistency and test–retest reliability
are strong for all three factors.
The Multidimensional Scale of Perceived Social
Support (MSPSS [30]),12 items. The MSPSS was
found to have good internal reliability and a strong
factorial validity according to a three-subscale
structure: Family, Friends, and Significant Others.
The Service Engagement Scale (SES [31]), 14 Items.
The scale has high internal consistency and retest
reliability and four sub-scales: availability, collaboration,
help-seeking, and treatment adherence.
The Insight Scale (IS [32]), 8 items. This scale
captures three dimensions of insight: perceived need
for treatment, awareness of illness, and re-labelling of
symptoms as pathological. The psychometric properties
of the scale have been called excellent [33].
One item (item 24) of the Addiction Severity Index
(ASI [34, 35]) will be used to measure the extent to
which respondents have been bothered in the past
30 days by problems with a.) alcohol, or b.) drugs.
Illness outcomes: symptoms and relapses The second-
ary outcomes on illness-management outcomes are
symptoms, health complaints & functional limitations,
Table 2 Instruments, data sources and times of measurement
Domain Aspect Instrument Data source Time of measurement
Patient file Patient Clinician M1 M2 M3
Bio-demographic data x x x x
Diagnosis x x x
Illness management Coping CSES x x x x
Social Support MSPSS x x x x
Treatment compliance SES x x x x
Insight Insight Scale (IS) x x x x
Addiction Item 24 of the ASI x x x x
Illness management + illness
outcomes
IMR scale, patient version x x x x
IMR scale, clinician version x x x x
illness outcomes Symptoms BSI x x x x
Hospitalisations Records of Mental Health
Institution
x x x
Health complaints and
functional limitations
EQ-5D x x x x
Subjective recovery Generic MHRM x x x x
Self-Stigma ISMI x x x x
Self-Esteem SERS-SF x x x x
Goals Granholm’s Goals Template x x x x
Satisfaction One question of the ROM x x x x
Objective recovery Social Functioning The SF Scale x x x x
Fidelity IMR-fidelity scale, GOI; x x x Between M1 & M2
IT-IS scale
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and relapses. These topics will be measured with the
following:
The Brief Symptom Inventory (BSI [36–38]), 53 items.
The authors report good validity, internal consistency
and test-retest reliability for the nine dimensions:
Psychoticism, Depression, Somatization, Phobic Anxiety,
Obsessive Compulsive, Interpersonal Sensitivity,
Anxiety, Hostility, and Paranoid Ideation; and also
good test-retest reliability for the three Global
Indices: global severity index (GSI), positive
symptom total (PST), and positive symptom
distress index (PSDI).
The EQ-5D [39], five items. This scale measures
primarily health complaints (in a broad sense) and
functional limitations. The EQ-5D is the Euro-QOL
self-report scale and has good psychometric
properties.
The number of relapses will be operationalised as the
number and duration of hospital admissions and num-
ber of emergency-department visits.
Recovery
In Mueser’s conceptual framework [2], the concept of
recovery is differentiated into subjective recovery and
objective recovery. The concept of subjective recovery is
complex. Mueser divides subjective recovery into per-
ceived recovery, sense of purpose and personal agency,
and divides objective recovery into social and role func-
tioning. As secondary outcome measures we will use five
scales to assess subjective recovery and one longer scale
for objective recovery.
Subjective recovery We will assess subjective recovery
using a specific recovery scale, and by assessing internal
stigma, quality of life, self-esteem and life-goals on the
basis of the following:
The Mental Health Recovery Measure (MHRM [40, 41];
authorized Dutch translation [42]), 30 items. The
Dutch version is a reliable measure in terms of
internal consistency; convergent and divergent
validity are generally acceptable [43]. The authors
differentiate three subscales; ‘self-empowerment’
(13 items), ‘learning and new potentials’ (15 items)
and ‘spirituality’ (2 items).
The Internal Stigma of Mental Illness (ISMI [44]); 29
items. This scale is designed to measure the subjective
experience of stigma, with subscales measuring
Alienation, Stereotype Endorsement, Perceived
Discrimination, Social Withdrawal and Stigma
Resistance. The ISMI has high internal consistency
and test-retest reliability. Construct validity and
divergent validity were supported by comparisons
with scales measuring related constructs.
One item of the Quality of Life section of the
Cumulative Needs for Care Monitor (CNCM [45]),
which asks: ‘’Can you tell me how satisfied you are
with your life as a whole?” This item correlates
strongly with the total score of this Quality of Life
section.
The Self-Esteem Rating Scale-Short Form (SERS-SF
[46]), 20 items. This scale has two subscales: positive
and negative self-esteem. It also has good internal
consistency, good test-retest reliability and adequate
convergent validity for people with schizophrenia.
In line with Muesers’ conceptual framework, we
consider improving on personal goals to be a medi-
ator variable between illness self-management and
recovery ([2], p. S35). We will measure this with
Granholm’s Goals Template [47], an instrument for
Goal Attainment Scaling that measures progress to-
wards goals in ten life domains: employment, housing,
relationships, school, self-care; leisure activities, addic-
tions, money-management, independence using trans-
portation, and general template. We have developed a
very short manual for this scale, whose psychometric
properties have not yet been investigated.
Objective recovery Objective recovery will be assessed
using the Social Functioning Scale [48]. Mueser de-
fines social and role functioning as aspects of object-
ive recovery. Both are covered with this scale, which
has 19 items and the following seven dimensions:
social withdrawal, relationships, social activities, recre-
ational activities, independence (competence), inde-
pendence (performance), and employment. This scale
has been described as reliable, valid, sensitive and re-
sponsive to change.
Cost-utility
The number and duration of outpatient treatment con-
tacts and inpatient days will be calculated in cost in
Euro’s. They are related with changes in quality of life
measured with the EQ-5D [39]. Cost-utility can be cal-
culated by transforming scores on the EQ-5D into so-
called QALYs [49]. To calculate cost-utility, only the cost
of health care consumption is included, not social costs
such as rent, benefits, etc.
Blinding
Thirteen of the above scales are self-report scales, and
two (IMRS-clinician version and SES) will be rated by
non-blinded clinicians who will not be involved in the
IMR training. Granholm’s Goals Template will be rated
by the blinded research assistants in an interview with
the clinician.
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At the second and third measurements, the measure-
ment procedure will be single-blinded: the research as-
sistants will not know whether a client is participating in
the experimental condition or the control condition; this
procedure will preclude experimenter’s bias. To ensure
this, clients and clinicians alike will be instructed before
the interview not to inform the interviewer in any way
about the client’s condition. At the end of each inter-
view, interviewers will answer the question whether they
have found out which condition the clients are in.
Sample size
On the basis of the effect sizes of the studies by Hasson-
Ohayon et al. (2007), Levitt et al. (2009) and Färdig et al.
(2011) [16–18], we anticipate a medium effect size of
0.40 on the primary outcome variable (self-rated IMR
scale, Mueser et al. 2004, 2005 [23, 24]). On the basis of
the power analyses with three times of measurement
(mixed models), equal allocation to the experimental
and control groups, a power of .80, alpha at 0.05, and an
effect size of .40, it will be necessary to randomize 148
clients: 74 to the experimental condition and 74 to the
CAU group [50, 51].
Randomisation
Because IMR is a relatively long-term care program-
me—in our pilot study at least 8 months at one session
per week—the drop-out from treatment may be rela-
tively high. Other studies had 29 % [17], 15 % [18]; 51 %
[20], and 72 % [15]. Due to the 50 % drop-out rate
expected from treatment in the experimental condition
(a pessimistic estimate), we have chosen to allocate more
clients to the experimental condition (IMR) than to the
CAU group (proportions of 3:2). We will randomise 200
clients (on the basis of a conservative calculation): 120
to the experimental condition and 80 to the CAU group.
Randomisation will be stratified by team. To ensure
the right distribution of clients per team in the two
groups, envelopes containing five lots per team will be
used each time. For this we will use a randomisation
plan from http://www.randomization.com. After com-
pleting the baseline interviews, the principal investigator
will allocate participants to the experimental group or
control group.
Statistical analysis
The analyses will be based on the intention-to-treat
principle. Generalized linear mixed models will be used
to investigate group difference between the experimental
and control conditions [52, 53], with times of measure-
ment nested within study participants. As well as the
main effects of time and condition, we will investigate
whether there is a time x condition interaction effect
with respect to symptoms, health complaints, number of
relapses and recovery. Because number of relapses is a
count variable, the analysis will use a mixed model for
the poisson or negative binomial distribution. We will
also test whether the addition of a random effect for the
time variable results in a better model fit in each of the
analyses. For the recovery outcome, we will investigate
the influence of illness management, symptoms, relapses
and progress on personal goals, as well as their inter-
action with time. Akaike’s Information Criterion (AIC
[54]) will be used for statistical model selection in these
analyses.
To explore associations between illness-management
outcomes and recovery outcomes, we will use structural
equation modelling. To investigate the associations be-
tween improvement of symptoms, recovery and fidelity
(within IMR + CAU), linear mixed models will be used,
with clients nested within IMR groups. As well as a fixed
effect for the trainer’s fidelity score, a random intercept
at the group level will be incorporated. Before testing
the first and second primary hypotheses, we will test the
fourth secondary hypothesis: ‘we expect that any im-
provement resulting from IMR + CAU will be associated
with the fidelity with which IMR is implemented.’ If fi-
delity has an effect, it will be included as a covariate in
the subsequent analyses.
Clients will be classified as completers of the study if
they have finished all three interviews. After the
intention-to-treat analyses, we will perform secondary
analyses to measure the effects in clients who have com-
pleted IMR.
Ethical considerations
The study protocol, information brochure and in-
formed consent form were consistent with the declar-
ation of Helsinki and approved by the Dutch Union
of Medical-Ethic Trial Committees for mental health
organisations (registration number of the Dutch National
Trial Register NTR 5033 http://www.trialregister.nl,
CCMO-no. NL 38605.078.12).
Discussion
As the four RCTs conducted on IMR have yielded mixed
results, more research is needed. We therefore aim to
compare the effectiveness of the IMR programme with
that of CAU in people with SMI. Our first primary hy-
pothesis is that IMR + CAU will lead to better illness
management and fewer symptoms and relapses than
CAU only. The second primary hypothesis is that IMR
+ CAU will lead to better ‘subjective’ and ‘objective’ re-
covery than CAU only. The first secondary hypothesis is
that the cost-utility of IMR + CAU will be better than
that of CAU. We intend to explore the working mecha-
nisms of IMR by testing a second secondary hypothesis
that better illness management will lead to fewer
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symptoms and relapses. We also intend to test a third
secondary hypothesis that better ‘distal outcomes’ (i.e.
recovery) will result from a combination of better ‘prox-
imal outcomes’ (i.e. better illness management and fewer
symptoms and relapses) and progress on personal goals.
Finally, in our fourth secondary hypothesis, we expect
that any improvement resulting from IMR + CAU will
be associated with the fidelity with which IMR is
implemented.
Our study has various strengths and limitations.
Strengths
The first strength is that our use of different outcome
measures for each domain will provide a thorough meas-
urement of the effects of IMR on illness management
and on subjective and objective recovery. And as well as
exploring the contribution made by various illness-
management variables to illness outcomes, we will also
explore the contribution that progress on personal goals
makes to subjective and objective recovery. In this way
we will be able to analyse the working mechanisms of
Mueser’s conceptual framework [2].
Other strengths of our study are that it will be con-
ducted in another country than the earlier RCTs. By in-
cluding 200 participants with various types of SMI, it
will also have a relatively large sample size. The numbers
of participants in the other completed RCTs were 210
[17], 104 [18], 41 [16] and 118 [15]. As the study will be
conducted in the everyday clinical practice of the two
participating mental health institutions, the generalis-
ability of its results will be good. The measurement pro-
cedure at the second and third time of measurement
will be single blinded.
Limitations
Firstly, no structured diagnostic interview will be used to
confirm the DSM-IV diagnosis. Practical considerations
underlay our choice of the clinical diagnosis reported by
clinicians on the basis of the medical records; due to the
limited relevance of a DSM-IV diagnosis to the present
study, this seems to be sufficient.
Another limitation is the chance of recruitment bias.
As we consider clinicians to be responsible for treat-
ment, it will be they who suggest that particular clients
participate in IMR, and who inform these clients about
the study. Although an interview with an assistant re-
searcher will be used to screen all clinicians’ total
caseloads for their potential suitability for IMR, and al-
though the clinicians are indeed supposed to ask all se-
lected clients to participate in IMR and to inform them
about the study, some clinicians may prefer certain cli-
ents for participation in IMR—those whose functioning
is better, for example. Some of these selected clients are
therefore likely to participate in this study. We will
explore which criteria the clinicians use to select partici-
pants for IMR.
A further limitation is that the clinicians who score
two questionnaires will not be blind for the condition.
On the other hand, they will not be involved in the IMR
training. Neither, due to the use of self-score question-
naires, will they be blind for the clients.
The use of multiple scales to assess aspects of object-
ive and subjective recovery is a limitation, as multiple
testing may introduce positive findings. However, given
the comprehensive nature of the IMR model and train-
ing programme, we felt that it would not be enough to
use IMR scales alone [23, 24], and that a more compre-
hensive set of scales was needed.
By limiting the cost-utility analyses to health care con-
sumption alone, we will not be able to include potential
reductions in social costs, such as those that might
occur if IMR participants manage their symptoms well
enough to be able to work. But a full assessment of costs
is beyond the scope of this study.
Finally, IMR will be offered in our study in a group
format, and will be compared with care as usual, which
will largely involve an individual format. Some of the
possible effect in a group format may be attributable to
peer-group support.
If evidence provides support for IMR, IMR may be
recommended as part of the guidelines for SMI care,
and be implemented more broadly. This will enable it to
meet a need for a structured psychosocial intervention
that supports illness management and recovery.
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